Sysmex - Public Comps and Valuation Multiples

Sysmex Overview

About Sysmex

Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.

Founded

1968

HQ

Employees

8.6K+

Website

sysmex.co.jp

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $3.4B

LTM EBITDA $883M

EV

$11.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sysmex Financials

Sysmex has a last 12-month revenue of $3.4B and a last 12-month EBITDA of $883M.

In the most recent fiscal year, Sysmex achieved revenue of $3.1B and an EBITDA of $750M.

Sysmex expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sysmex valuation multiples based on analyst estimates

Sysmex P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$2.7B	$3.1B	XXX	XXX	XXX
Gross Profit	$1.3B	$1.4B	XXX	XXX	XXX
Gross Margin	46%	47%	XXX	XXX	XXX
EBITDA	$678M	$750M	XXX	XXX	XXX
EBITDA Margin	25%	24%	XXX	XXX	XXX
Net Profit	$293M	$304M	XXX	XXX	XXX
Net Margin	11%	10%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Sysmex Stock Performance

As of April 15, 2025, Sysmex's stock price is JPY 2686 (or $18).

Sysmex has current market cap of JPY 1.68T (or $11.1B), and EV of JPY 1.65T (or $11.0B).

See Sysmex trading valuation data

Sysmex Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$11.0B	$11.1B	XXX	XXX	XXX	XXX	$0.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sysmex Valuation Multiples

As of April 15, 2025, Sysmex has market cap of $11.1B and EV of $11.0B.

Sysmex's trades at 3.2x LTM EV/Revenue multiple, and 12.4x LTM EBITDA.

Analysts estimate Sysmex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Sysmex and 10K+ public comps

Sysmex Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$11.0B	XXX	XXX	XXX
EV/Revenue	3.3x	XXX	XXX	XXX
EV/EBITDA	13.0x	XXX	XXX	XXX
P/E	29.8x	XXX	XXX	XXX
P/E/Growth	2.0x	XXX	XXX	XXX
EV/FCF	46.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sysmex Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sysmex Valuation Multiples

Sysmex's NTM/LTM revenue growth is 8%

Sysmex's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Sysmex's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Sysmex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Sysmex and other 10K+ public comps

Sysmex Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	12%	XXX	XXX	XXX	XXX
EBITDA Margin	25%	XXX	XXX	XXX	XXX
EBITDA Growth	11%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	33%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.4M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	29%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	7%	XXX	XXX	XXX	XXX
Opex to Revenue	35%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry